# Mediolanum Farmaceutici S.p.A.

> Mediolanum Farmaceutici S.p.A. is a VC fund in Milan backing Biopharma and Therapeutics. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Milan, Italy
- Total investments: 2
- Last investment: Mar 2024
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/mediolanum-farmaceutici-spa
- Website: http://www.mediolanum-farma.it/chi-siamo/company-overview.html

Mediolanum Farmaceutici S.p.A. is a VC fund in Milan focused on Biopharma and Therapeutics. The Group has strengthened its presence in Italy and has grown to become an international pharmaceutical company. The research for the development of original and innovative products, to improve the health and quality of life of people, is an integral and fundamental part of the activities of the company that has fully developed four productsand, over the years, has obtained over 700 patents for more than 40 countries . The Group enjoys an image of seriousness and dynamism and believes in promoting the culture of Corporate Social Responsibility in order to provide a service to the community.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 50% |
| Therapeutics | 1 | 50% |
| Biotechnology | 1 | 50% |
| Pharmaceutical | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $8.7M | Post-IPO Equity | Mar 15, 2024 |  |
| Acticor Biotech | Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $12.9M | Post-IPO Equity | Mar 09, 2023 |  |

2 of 2 investments shown.

## Co-investors
- [UI Investissement](https://shizune.co/investors/profile/ui-gestion) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Mediolanum Farmaceutici S.p.A. invest in?

Mediolanum Farmaceutici S.p.A. invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Mediolanum Farmaceutici S.p.A. last invest?

The most recent investment recorded for Mediolanum Farmaceutici S.p.A. closed in Mar 2024. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co